Founded in 2000, SomaLogic® is a global leader in proteomics. Our pioneering SomaScan® Platform provides more coverage of the proteome than any other technology from only 55 µL of a variety of body fluids, including plasma, serum, CSF, urine, and more. We currently measure 7,000 proteins – more than twice as many as any other proteomics platform – and we are quickly moving toward 10,000 proteins.

The proprietary SomaScan Assay measures proteins with high specificity, high throughput, and high reproducibility, which enables the possibility of faster, more precise drug discovery. Our A.I. and machine learning-powered bioinformatics algorithms, operated in tandem with the company’s database of more than 550,000 protein samples, helped to create a growing suite of SomaSignal™ tests. These tests are clinical proteomic diagnostics that provide additional insights into the current health status of patients and the future risk of conditions and diseases. Custom and disease-specific panels are also available for a more targeted approach.

Our key disease areas: Cardiovascular Disease, Diabetes, Neurology, Oncology/Immunology, Nonalcoholic Fatty Liver Disease, and Rare Disease